Highlights
- Alcidion reported FY26 Revenue of AUD 51.6 million, a 27% increase.
- Annual Recurring Revenue reached AUD 38.3 million, up 34%.
- Alcidion (ASX:ALC) approved a ten-for-one share consolidation in November 2026.
- Contracted FY27 revenue reached AUD 50.0 million by September 2026.
Alcidion (ASX:ALC) develops clinical software for hospitals and health networks, including its Miya patient-flow and decision-support platform. FY26 growth, contract extensions across Australia and the United Kingdom, and a November 2026 share consolidation are distinct developments. The operational discussion centres on recurring software income, delivery obligations and the company’s updated outlook rather than movements in quoted share prices.
FY26 Revenue and Recurring Software Income
Alcidion reported revenue of AUD 51.6 million for FY26, an increase of 27%, while annual recurring revenue reached AUD 38.3 million, up 34%. Underlying EBITDA was AUD 6.8 million and reported net profit after tax was AUD 2.3 million. At the June balance date, the group reported AUD 20.6 million of cash and no debt. These measures show the difference between recognised sales, the recurring revenue base and cash resources available for implementation.
Gross Margin declined to 80.3% from 88.2%. Management attributed the change to a greater proportion of third-party product resale. The distinction matters because growth driven by internally developed software can carry a different margin profile from revenue involving products supplied by external vendors. Accordingly, an expansion in recurring revenue need not produce an identical increase in gross profit.
Hospital Contracts and FY27 Revenue Visibility
The company announced a deployment of Miya Precision for the Northern Care Alliance in the United Kingdom on 30 September 2026. Its October update described an expanded agreement worth AUD 7.5 million over three years, with around AUD 4.5 million expected to be recognised in FY27. It also reported an extension of Miya services into Whanganui Hospital through the Health New Zealand MidCentral relationship.
Contracted revenue for FY27 stood at AUD 50.0 million by 30 September 2026, up 38% according to the company update. Management expects FY27 revenue and underlying EBITDA to exceed FY26, but did not provide precise full-year numerical targets. Contracted revenue represents visibility rather than proof that all implementation work and recognition milestones have already been completed.
What the Ten-for-One Consolidation Changes
Shareholders approved a consolidation of ten existing shares into one new share at the 12 November 2026 annual general meeting. The notice indicated that approximately 1.35 billion shares would become roughly 135 million, subject to rounding. Deferred settlement trading in reorganised shares was scheduled from 16 November, with normal trading expected to resume on 25 November.
The transaction does not itself raise Capital or change shareholders’ proportional ownership. Prices before and after consolidation must be adjusted to the same share basis for a meaningful comparison. The company also announced an on-market buy-back of up to 10% of issued capital, a separate capital-management measure whose actual purchases depend on subsequent execution.
Implementation Risks and the Next Reporting Period
Healthcare software contracts can involve lengthy procurement, configuration and deployment stages. Alcidion is integrating the Kyra patient-flow products acquired from Telstra Health in June 2026, while the proportion of resale revenue will continue to influence margins. Public-sector budgets and hospital implementation timetables remain relevant uncertainties.
The next reported periods will clarify whether the contracted FY27 revenue pipeline converts into recognised income and whether operating profitability develops alongside it. The share consolidation changes the quoted share unit, while contract delivery, retention and cost management determine operational outcomes.
Key Insights
Alcidion’s FY26 results showed higher revenue and recurring income, while gross margin reflected its changing revenue mix. New hospital deployments and contracted FY27 revenue provide measurable Business milestones. The capital consolidation is an administrative restructuring, not an Earnings driver; delivery and margin performance remain the substantive questions.






Please wait processing your request...